Galenica AB is a contract research organisation (CRO) providing services in the field of pharmaceutical technology. The company has broad skills and experience in formulation, production and quality control of pharmaceuticals.

The parties have agreed to a development plan, including production technology transfer, testing of biological activity of the product and development of suitable formulations.

‘’BAMLET is a fascinating molecule with potent effects on tumor cells and in animal models of cancer’’ says Catharina Svanborg, Chairman, Hamlet Pharma.

‘’We are pleased to move forward with our second drug candidate and extend the Hamlet Pharma portfolio’’, says Mats Persson, CEO, Hamlet Pharma.

This disclosure contains information that Hamlet is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 30-11-2021 08:50 CET.